A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted

Summary

This is a phase 1 first-in-human clinical trial to assess the safety, tolerability, and immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted, in up to 48 healthy adult HIV-negative volunteers.

Timeline

Start

2018-06-15

Primary completion

2020-01-17

Completion

2021-08-13

Publications

• Yan H, Peng Y, Zhang J, Peng R, Feng X, Su J, Yi H, Lu Y, Gao S, Liu J, Yang M, Liu X, Gao S, Chen Z. Rapid and highly potent humoral responses to mpox nanovaccine candidates adjuvanted by thermostable scaffolds. Vaccine. 2024 Mar 19;42(8):2072-2080. doi: 10.1016/j.vaccine.2024.02.027. Epub 2024 Feb 28.

Drugs

Indications